BACKGROUND:African-Americans are likely to develop hypertension and hypertensive nephrosclerosis. This grave prognosis, coupled with familial aggregation of end-stage renal disease (ESRD) in Blacks, prompts a search for genetic risk factors for ESRD. Recent evidence implicates a crucial role for the sympathetic nervous system in progressive renal disease. METHODS: We used the African-American Study of Kidney Disease to probe whether beta2-adrenergic receptor (ADRB2) predicts glomerular filtration rate (GFR) decline rate. A total of 580 participants were included. Baseline GFR was 51.2 +/- 0.5 ml/min/1.73 m2. Subjects were randomized in a 2 x 3 block design: to intensively lowered (MAP < or = 92 mm Hg) versus 'usual' (MAP = 102-107 mm Hg) blood pressure goal groups, and also divided by three randomized antihypertensive drugs (ramipril, metoprolol, or amlodipine). We scored 4 SNPs at the ADRB2 locus. RESULTS: Haplotypes at ADRB2 predicted chronic GFR decline rate, GFR declined more slowly in individuals with haplotype-1 (-804G-->173T-->16Gly-->27GIn), and faster in those who carried haplotype-3 (-804G-->173T-->16Arg-->27Gln). ADRB2 genotype interacted with antihypertensive drug class to influence GFR slope (p = 0.001-0.037). We extended our findings to an independent case/control sample of Black hypertensive ESRD, in which we found that variant Gly16Arg that tagged the GFR slope-determining ADRB2 haplotype also conferred risk for the ESRD trait in Blacks. CONCLUSIONS: The GFR decline/progression rate in hypertensive renal disease is controlled in part by genetic variation within the adrenergic pathway. Copyright 2010 S. Karger AG, Basel.
RCT Entities:
BACKGROUND: African-Americans are likely to develop hypertension and hypertensive nephrosclerosis. This grave prognosis, coupled with familial aggregation of end-stage renal disease (ESRD) in Blacks, prompts a search for genetic risk factors for ESRD. Recent evidence implicates a crucial role for the sympathetic nervous system in progressive renal disease. METHODS: We used the African-American Study of Kidney Disease to probe whether beta2-adrenergic receptor (ADRB2) predicts glomerular filtration rate (GFR) decline rate. A total of 580 participants were included. Baseline GFR was 51.2 +/- 0.5 ml/min/1.73 m2. Subjects were randomized in a 2 x 3 block design: to intensively lowered (MAP < or = 92 mm Hg) versus 'usual' (MAP = 102-107 mm Hg) blood pressure goal groups, and also divided by three randomized antihypertensive drugs (ramipril, metoprolol, or amlodipine). We scored 4 SNPs at the ADRB2 locus. RESULTS: Haplotypes at ADRB2 predicted chronic GFR decline rate, GFR declined more slowly in individuals with haplotype-1 (-804G-->173T-->16Gly-->27GIn), and faster in those who carried haplotype-3 (-804G-->173T-->16Arg-->27Gln). ADRB2 genotype interacted with antihypertensive drug class to influence GFR slope (p = 0.001-0.037). We extended our findings to an independent case/control sample of Black hypertensiveESRD, in which we found that variant Gly16Arg that tagged the GFR slope-determining ADRB2 haplotype also conferred risk for the ESRD trait in Blacks. CONCLUSIONS: The GFR decline/progression rate in hypertensive renal disease is controlled in part by genetic variation within the adrenergic pathway. Copyright 2010 S. Karger AG, Basel.
Authors: Fangwen Rao; Jennifer Wessel; Gen Wen; Lian Zhang; Brinda K Rana; Brian P Kennedy; Tiffany A Greenwood; Rany M Salem; Yuqing Chen; Srikrishna Khandrika; Bruce A Hamilton; Douglas W Smith; Niels-Henrik Holstein-Rathlou; Michael G Ziegler; Nicholas J Schork; Daniel T O'Connor Journal: Hypertension Date: 2007-03-12 Impact factor: 10.190
Authors: Barry I Freedman; Pamela J Hicks; Meredith A Bostrom; Mary E Cunningham; Yongmei Liu; Jasmin Divers; Jeffrey B Kopp; Cheryl A Winkler; George W Nelson; Carl D Langefeld; Donald W Bowden Journal: Kidney Int Date: 2009-01-28 Impact factor: 10.612
Authors: Yee-Wei Lee; Vernon M S Oh; Edwin Garcia; Elizabeth A Taylor; Huimin Wu; Eric Ph Yap; Gbenga R Kazeem; Mark J Caulfield; Patricia B Munroe Journal: J Hypertens Date: 2004-11 Impact factor: 4.844
Authors: Rany M Salem; Peter E Cadman; Yuqing Chen; Fangwen Rao; Gen Wen; Bruce A Hamilton; Brinda K Rana; Douglas W Smith; Mats Stridsberg; Harry J Ward; Manjula Mahata; Sushi K Mahata; Donald W Bowden; Pamela J Hicks; Barry I Freedman; Nicholas J Schork; Daniel T O'Connor Journal: J Am Soc Nephrol Date: 2008-01-30 Impact factor: 10.121
Authors: Maple M Fung; Yuqing Chen; Michael S Lipkowitz; Rany M Salem; Vibha Bhatnagar; Manjula Mahata; Caroline M Nievergelt; Fangwen Rao; Sushil K Mahata; Nicholas J Schork; Victoria H Brophy; Daniel T O'Connor Journal: Nephrol Dial Transplant Date: 2009-09-10 Impact factor: 5.992
Authors: K H Buetow; M Edmonson; R MacDonald; R Clifford; P Yip; J Kelley; D P Little; R Strausberg; H Koester; C R Cantor; A Braun Journal: Proc Natl Acad Sci U S A Date: 2001-01-02 Impact factor: 11.205
Authors: C Barrett Bowling; Margaret A Feller; Marjan Mujib; Pushkar P Pawar; Yan Zhang; O James Ekundayo; Inmaculada B Aban; Thomas E Love; Paul W Sanders; Stefan D Anker; Gregg C Fonarow; Ali Ahmed Journal: Am J Nephrol Date: 2011-07-04 Impact factor: 3.754
Authors: Guido Grassi; Gino Seravalle; Lorenzo Ghiadoni; Giovanni Tripepi; Rosa Maria Bruno; Giuseppe Mancia; Carmine Zoccali Journal: Clin J Am Soc Nephrol Date: 2011-09-22 Impact factor: 8.237
Authors: Ali Kamiar; Keyvan Yousefi; Julian C Dunkley; Keith A Webster; Lina A Shehadeh Journal: Am J Physiol Regul Integr Comp Physiol Date: 2021-02-10 Impact factor: 3.619
Authors: Dalal N Pasha; Jason T Davis; Fangwen Rao; Yuqing Chen; Gen Wen; Maple M Fung; Manjula Mahata; Kuixing Zhang; Danuta Trzebinska; Maja Mustapic; C Makena Hightower; Michael S Lipkowitz; Ming Ji; Michael G Ziegler; Caroline M Nievergelt; Daniel T O'Connor Journal: PLoS One Date: 2013-12-31 Impact factor: 3.240
Authors: Michael S Lipkowitz; Barry I Freedman; Carl D Langefeld; Mary E Comeau; Donald W Bowden; W H Linda Kao; Brad C Astor; Erwin P Bottinger; Sudha K Iyengar; Paul E Klotman; Richard G Freedman; Weijia Zhang; Rulan S Parekh; Michael J Choi; George W Nelson; Cheryl A Winkler; Jeffrey B Kopp Journal: Kidney Int Date: 2012-07-25 Impact factor: 10.612
Authors: Mathias Gorski; Adrienne Tin; Maija Garnaas; Gearoid M McMahon; Audrey Y Chu; Bamidele O Tayo; Cristian Pattaro; Alexander Teumer; Daniel I Chasman; John Chalmers; Pavel Hamet; Johanne Tremblay; Marc Woodward; Thor Aspelund; Gudny Eiriksdottir; Vilmundur Gudnason; Tamara B Harris; Lenore J Launer; Albert V Smith; Braxton D Mitchell; Jeffrey R O'Connell; Alan R Shuldiner; Josef Coresh; Man Li; Paul Freudenberger; Edith Hofer; Helena Schmidt; Reinhold Schmidt; Elizabeth G Holliday; Paul Mitchell; Jie Jin Wang; Ian H de Boer; Guo Li; David S Siscovick; Zoltan Kutalik; Tanguy Corre; Peter Vollenweider; Gérard Waeber; Jayanta Gupta; Peter A Kanetsky; Shih-Jen Hwang; Matthias Olden; Qiong Yang; Mariza de Andrade; Elizabeth J Atkinson; Sharon L R Kardia; Stephen T Turner; Jeanette M Stafford; Jingzhong Ding; Yongmei Liu; Cristina Barlassina; Daniele Cusi; Erika Salvi; Jan A Staessen; Paul M Ridker; Harald Grallert; Christa Meisinger; Martina Müller-Nurasyid; Bernhard K Krämer; Holly Kramer; Sylvia E Rosas; Ilja M Nolte; Brenda W Penninx; Harold Snieder; M Fabiola Del Greco; Andre Franke; Ute Nöthlings; Wolfgang Lieb; Stephan J L Bakker; Ron T Gansevoort; Pim van der Harst; Abbas Dehghan; Oscar H Franco; Albert Hofman; Fernando Rivadeneira; Sanaz Sedaghat; André G Uitterlinden; Stefan Coassin; Margot Haun; Barbara Kollerits; Florian Kronenberg; Bernhard Paulweber; Nicole Aumann; Karlhans Endlich; Mike Pietzner; Uwe Völker; Rainer Rettig; Vincent Chouraki; Catherine Helmer; Jean-Charles Lambert; Marie Metzger; Benedicte Stengel; Terho Lehtimäki; Leo-Pekka Lyytikäinen; Olli Raitakari; Andrew Johnson; Afshin Parsa; Murielle Bochud; Iris M Heid; Wolfram Goessling; Anna Köttgen; W H Linda Kao; Caroline S Fox; Carsten A Böger Journal: Kidney Int Date: 2014-12-10 Impact factor: 10.612